Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%

CASTLE BIOSCIENCES INC

2023-FY EPS reported -$2.14 revenue$219,788,000

Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.
Delivered 70,429 total test reports in 2023, up 59% YoY; Q4 reports 20,284, up 60% YoY.
TissueCypher Barrett's Esophagus test reports surged 328% YoY in 2023; IDgenetix up 236%.
Year-end cash, equivalents and short-term investments expected ~$243M.
Preliminary results, subject to audit completion; final results may differ.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CASTLE BIOSCIENCES INC reported the fourth quarter and year ended Dec. 31, 2023 results: revenue more than $210 million.

Period: the fourth quarter and year ended Dec. 31, 2023
Revenue: more than $210 million
Result: preliminary results

Exact text from the filing

contains --- EX-99.2 (EX-99.2) --- Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.